BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meyer A, Semenzato L, Zureik M, Weill A, Carbonnel F, Dray-Spira R. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther 2021;54:160-6. [PMID: 34110040 DOI: 10.1111/apt.16410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022:gutjnl-2021-326784. [PMID: 35477864 DOI: 10.1136/gutjnl-2021-326784] [Reference Citation Analysis]
2 Park YE, Lee YJ, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Kim SE, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement]. Korean J Gastroenterol 2021;78:105-16. [PMID: 34446633 DOI: 10.4166/kjg.2021.112] [Reference Citation Analysis]
3 Howden CW, Loomba R. A Message from the Editors. Aliment Pharmacol Ther 2022;55:4-5. [PMID: 34907571 DOI: 10.1111/apt.16701] [Reference Citation Analysis]
4 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hadi Y, Dulai PS, Kupec J, Mohy-Ud-Din N, Jairath V, Farraye FA, Kochhar GS. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis. Aliment Pharmacol Ther 2021. [PMID: 34904240 DOI: 10.1111/apt.16730] [Reference Citation Analysis]
6 Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000774. [PMID: 34725056 DOI: 10.1136/bmjgast-2021-000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Amiot A, Seksik P, Reimund J, Nachury M, Altwegg R, Bourreille A, Viennot S, Fumery M, Roblin X, Serrero M, Allez M, Painchart C, Chanteloup E, Vuitton L, Fotsing G, Buisson A, Coulibaly B, Nancey S, Gilletta C, Plastaras L, Abitbol V, Guillo L, Simon M, Nahon S, Laharie D, Peyrin-biroulet L, Bouguen G, Amiot A, Gagniere C, Nachury M, Wils P, Bouhnik Y, Stefanescu C, Treton X, Martins C, Uzzan M, Serrero M, Guillo L, Roblin X, Tedesco ED, Beaugerie L, Seksik P, Bourrier A, Landmann C, Kirchgesner J, Sokol H, Buisson A, Nancey S, Boschetti G, Gay C, Danion P, Flourié B, Abitbol V, Malamut G, Reimund J, Caron B, Vuitton L, Peyrin-biroulet L, Zallot C, Gilletta C, Allez M, Gornet J, Baudry C, Viennot S, Bourreille A, Trang-poisson C, Boualit M, Painchart C, Plastaras L, Altwegg R, Boivineau L, Fumery M, Laharie D, Riviere P, Poullenot F, Coffin B, Duboc H, Nahon S, Simon M, Coulibaly B, Chanteloup E, Fotsing G. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.011] [Reference Citation Analysis]